Table 2 Subgroup and meta-regression analysis

Continent

0.92

0.82

Asia

6

0.72 (0.62, 0.81)

72.40%

0.91 (0.82, 0.98)

88.66%

Non-Asian

4

0.60 (0.45, 0.76)

71.16%

0.89 (0.75, 1.00)

0.00%

Study direction

0.79

0.67

Retrospective

6

0.68 (0.55, 0.81)

70.51%

0.96 (0.92, 1.00)

54.57%

Prospective

4

0.75 (0.59, 0.91)

80.85%

0.82 (0.73, 0.91)

75.21%

Type of study

0.44

0.51

Cohort

7

0.70 (0.57, 0.83)

74.50%

0.82 (0.74, 0.91)

75.21%

Case–control

3

0.77 (0.53, 1.00)

0.00%

0.96 (0.92, 1.00)

10.12%

Patients were Severely ill or immunocompromised

0.17

0.18

Yes

1

0.91 (0.94, 1.00)

/

0.77 (0.26, 1.00)

/

No

9

0.67 (0.58, 0.75)

68.56%

0.89 (0.82, 0.97)

86.15%

Sample method

0.28

0.96

Frozen

4

0.67 (0.53, 0.81)

77.03%

0.83 (0.68, 0.97)

80.59%

Fresh

6

0.68 (0.56, 0.80)

65.60%

0.92 (0.86, 0.98)

65.66%

Pathogen type

0.90

0.01

Mixed

6

0.75 (0.63, 0.87)

70.81%

0.83 (0.78, 0.88)

83.80%

Isolated

4

0.61 (0.45, 0.76)

26.20%

0.94 (0.87, 0.98)

0.00%

Sequencing platform

0.87

0.79

BGISEQ

3

0.77 (0.64, 0.90)

0.00%

0.93 (0.86, 0.97)

0.00%

Illumina

7

0.64 (0.53, 0.74)

70.69%

0.88 (0.74, 0.95)

86.85%